Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model

Hsuen Wen Chang, Min Ju Wu, Zih Miao Lin, Chueh Yi Wang, Shu Yun Cheng, Yen Kuang Lin, Yen Hung Chow, Hui Ju Ch'ang, Vincent H.S. Chang

研究成果: 雜誌貢獻文章

摘要

Lung cancer is one of the major cause of cancer-related deaths worldwide. The poor prognosis and resistance to both radiation and chemotherapy urged the development of potential targets for lung cancer treatment. In this study, using a network-based cellular signature bioinformatics approach, we repurposed a clinically approved mTOR inhibitor for renal cell carcinomans, temsirolimus, as the potential therapeutic candidate for lung adenocarcinoma. The PI3K-AKT-mTOR pathway is known as one of the most frequently dysregulated pathway in cancers, including non-small-cell lung cancer. By using a well-documented lung adenocarcinoma mouse model of human pathophysiology, we examined the effect of temsirolimus on the growth of lung adenocarcinoma in vitro and in vivo. In addition, temsirolimus combined with reduced doses of cisplatin and gemcitabine significantly inhibited the lung tumor growth in the lung adenocarcinoma mouse model compared with the temsirolimus alone or the conventional cisplatin-gemcitabine combination. Functional imaging techniques and microscopic analyses were used to reveal the response mechanisms. Extensive immunohistochemical analyses were used to demonstrate the apparent effects of combined treatments on tumor architecture, vasculature, apoptosis, and the mTOR-pathway. The present findings urge the further exploration of temsirolimus in combination with chemotherapy for treating lung adenocarcinoma.

原文英語
文章編號778
頁(從 - 到)778
期刊Frontiers in Pharmacology
9
發行號JUL
DOIs
出版狀態已發佈 - 七月 24 2018

指紋

Therapeutic Uses
gemcitabine
Cisplatin
Lung Neoplasms
Neoplasms
Growth
Combination Drug Therapy
Computational Biology
Phosphatidylinositol 3-Kinases
Non-Small Cell Lung Carcinoma
Therapeutics
Adenocarcinoma of lung
temsirolimus
Radiation
Apoptosis
Kidney
Drug Therapy
Lung

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

引用此文

Chang, H. W., Wu, M. J., Lin, Z. M., Wang, C. Y., Cheng, S. Y., Lin, Y. K., ... Chang, V. H. S. (2018). Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model. Frontiers in Pharmacology, 9(JUL), 778. [778]. https://doi.org/10.3389/fphar.2018.00778

Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model. / Chang, Hsuen Wen; Wu, Min Ju; Lin, Zih Miao; Wang, Chueh Yi; Cheng, Shu Yun; Lin, Yen Kuang; Chow, Yen Hung; Ch'ang, Hui Ju; Chang, Vincent H.S.

於: Frontiers in Pharmacology, 卷 9, 編號 JUL, 778, 24.07.2018, p. 778.

研究成果: 雜誌貢獻文章

Chang, HW, Wu, MJ, Lin, ZM, Wang, CY, Cheng, SY, Lin, YK, Chow, YH, Ch'ang, HJ & Chang, VHS 2018, 'Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model', Frontiers in Pharmacology, 卷 9, 編號 JUL, 778, 頁 778. https://doi.org/10.3389/fphar.2018.00778
Chang, Hsuen Wen ; Wu, Min Ju ; Lin, Zih Miao ; Wang, Chueh Yi ; Cheng, Shu Yun ; Lin, Yen Kuang ; Chow, Yen Hung ; Ch'ang, Hui Ju ; Chang, Vincent H.S. / Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model. 於: Frontiers in Pharmacology. 2018 ; 卷 9, 編號 JUL. 頁 778.
@article{0a2f6f87b5fb4c1aa11aa4a9dafa8e70,
title = "Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model",
abstract = "Lung cancer is one of the major cause of cancer-related deaths worldwide. The poor prognosis and resistance to both radiation and chemotherapy urged the development of potential targets for lung cancer treatment. In this study, using a network-based cellular signature bioinformatics approach, we repurposed a clinically approved mTOR inhibitor for renal cell carcinomans, temsirolimus, as the potential therapeutic candidate for lung adenocarcinoma. The PI3K-AKT-mTOR pathway is known as one of the most frequently dysregulated pathway in cancers, including non-small-cell lung cancer. By using a well-documented lung adenocarcinoma mouse model of human pathophysiology, we examined the effect of temsirolimus on the growth of lung adenocarcinoma in vitro and in vivo. In addition, temsirolimus combined with reduced doses of cisplatin and gemcitabine significantly inhibited the lung tumor growth in the lung adenocarcinoma mouse model compared with the temsirolimus alone or the conventional cisplatin-gemcitabine combination. Functional imaging techniques and microscopic analyses were used to reveal the response mechanisms. Extensive immunohistochemical analyses were used to demonstrate the apparent effects of combined treatments on tumor architecture, vasculature, apoptosis, and the mTOR-pathway. The present findings urge the further exploration of temsirolimus in combination with chemotherapy for treating lung adenocarcinoma.",
keywords = "Chemotherapy, Drug repositioning, Lung adenocarcinoma, mTOR inhibitor, Temsirolimus",
author = "Chang, {Hsuen Wen} and Wu, {Min Ju} and Lin, {Zih Miao} and Wang, {Chueh Yi} and Cheng, {Shu Yun} and Lin, {Yen Kuang} and Chow, {Yen Hung} and Ch'ang, {Hui Ju} and Chang, {Vincent H.S.}",
year = "2018",
month = "7",
day = "24",
doi = "10.3389/fphar.2018.00778",
language = "English",
volume = "9",
pages = "778",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

TY - JOUR

T1 - Therapeutic effect of repurposed temsirolimus in lung adenocarcinoma model

AU - Chang, Hsuen Wen

AU - Wu, Min Ju

AU - Lin, Zih Miao

AU - Wang, Chueh Yi

AU - Cheng, Shu Yun

AU - Lin, Yen Kuang

AU - Chow, Yen Hung

AU - Ch'ang, Hui Ju

AU - Chang, Vincent H.S.

PY - 2018/7/24

Y1 - 2018/7/24

N2 - Lung cancer is one of the major cause of cancer-related deaths worldwide. The poor prognosis and resistance to both radiation and chemotherapy urged the development of potential targets for lung cancer treatment. In this study, using a network-based cellular signature bioinformatics approach, we repurposed a clinically approved mTOR inhibitor for renal cell carcinomans, temsirolimus, as the potential therapeutic candidate for lung adenocarcinoma. The PI3K-AKT-mTOR pathway is known as one of the most frequently dysregulated pathway in cancers, including non-small-cell lung cancer. By using a well-documented lung adenocarcinoma mouse model of human pathophysiology, we examined the effect of temsirolimus on the growth of lung adenocarcinoma in vitro and in vivo. In addition, temsirolimus combined with reduced doses of cisplatin and gemcitabine significantly inhibited the lung tumor growth in the lung adenocarcinoma mouse model compared with the temsirolimus alone or the conventional cisplatin-gemcitabine combination. Functional imaging techniques and microscopic analyses were used to reveal the response mechanisms. Extensive immunohistochemical analyses were used to demonstrate the apparent effects of combined treatments on tumor architecture, vasculature, apoptosis, and the mTOR-pathway. The present findings urge the further exploration of temsirolimus in combination with chemotherapy for treating lung adenocarcinoma.

AB - Lung cancer is one of the major cause of cancer-related deaths worldwide. The poor prognosis and resistance to both radiation and chemotherapy urged the development of potential targets for lung cancer treatment. In this study, using a network-based cellular signature bioinformatics approach, we repurposed a clinically approved mTOR inhibitor for renal cell carcinomans, temsirolimus, as the potential therapeutic candidate for lung adenocarcinoma. The PI3K-AKT-mTOR pathway is known as one of the most frequently dysregulated pathway in cancers, including non-small-cell lung cancer. By using a well-documented lung adenocarcinoma mouse model of human pathophysiology, we examined the effect of temsirolimus on the growth of lung adenocarcinoma in vitro and in vivo. In addition, temsirolimus combined with reduced doses of cisplatin and gemcitabine significantly inhibited the lung tumor growth in the lung adenocarcinoma mouse model compared with the temsirolimus alone or the conventional cisplatin-gemcitabine combination. Functional imaging techniques and microscopic analyses were used to reveal the response mechanisms. Extensive immunohistochemical analyses were used to demonstrate the apparent effects of combined treatments on tumor architecture, vasculature, apoptosis, and the mTOR-pathway. The present findings urge the further exploration of temsirolimus in combination with chemotherapy for treating lung adenocarcinoma.

KW - Chemotherapy

KW - Drug repositioning

KW - Lung adenocarcinoma

KW - mTOR inhibitor

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=85050585852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050585852&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00778

DO - 10.3389/fphar.2018.00778

M3 - Article

VL - 9

SP - 778

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUL

M1 - 778

ER -